Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in NovemberCLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren’s disease in DecemberCLN-049 (FLT3 TCE) updated data from the Phase 1 dose escalation study in DecemberCAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE N…